Alyeska Investment Group L.P. boosted its stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 31.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 110,797 shares of the biopharmaceutical company’s stock after purchasing an additional 26,348 shares during the quarter. Alyeska Investment Group L.P. owned approximately 0.30% of Sage Therapeutics worth $6,903,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the business. Cowen Inc. purchased a new stake in Sage Therapeutics during the 3rd quarter worth about $1,246,000. Oppenheimer Asset Management Inc. increased its holdings in shares of Sage Therapeutics by 412.9% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 1,944 shares of the biopharmaceutical company’s stock valued at $122,000 after acquiring an additional 1,565 shares during the last quarter. Allianz Asset Management GmbH increased its holdings in shares of Sage Therapeutics by 67.2% in the 3rd quarter. Allianz Asset Management GmbH now owns 7,654 shares of the biopharmaceutical company’s stock valued at $477,000 after acquiring an additional 3,076 shares during the last quarter. Envestnet Asset Management Inc. increased its holdings in shares of Sage Therapeutics by 70.7% in the 3rd quarter. Envestnet Asset Management Inc. now owns 2,906 shares of the biopharmaceutical company’s stock valued at $182,000 after acquiring an additional 1,204 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its holdings in shares of Sage Therapeutics by 9.3% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 151,026 shares of the biopharmaceutical company’s stock valued at $9,409,000 after acquiring an additional 12,847 shares during the last quarter. Institutional investors own 95.40% of the company’s stock.

SAGE has been the topic of a number of recent analyst reports. SunTrust Banks increased their price objective on Sage Therapeutics to $178.00 and gave the company a “positive” rating in a report on Friday. Canaccord Genuity dropped their price objective on Sage Therapeutics from $110.00 to $81.00 and set a “buy” rating on the stock in a report on Tuesday, September 12th. Bank of America dropped their price objective on Sage Therapeutics from $103.00 to $101.00 and set a “buy” rating on the stock in a report on Thursday, November 16th. Cowen reiterated a “buy” rating on shares of Sage Therapeutics in a report on Monday. Finally, Royal Bank of Canada reiterated a “buy” rating and issued a $117.00 price objective on shares of Sage Therapeutics in a report on Wednesday, October 18th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $171.21.

Sage Therapeutics, Inc. (SAGE) opened at $163.33 on Tuesday. Sage Therapeutics, Inc. has a 12 month low of $44.55 and a 12 month high of $173.36.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.98) by $0.01. The firm’s revenue was up .0% on a year-over-year basis. sell-side analysts predict that Sage Therapeutics, Inc. will post -7.4 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Alyeska Investment Group L.P. Buys 26,348 Shares of Sage Therapeutics, Inc. (SAGE)” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/12/12/alyeska-investment-group-l-p-buys-26348-shares-of-sage-therapeutics-inc-sage.html.

Sage Therapeutics Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Institutional Ownership by Quarter for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Stock Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related stocks with our FREE daily email newsletter.